Zhai B, Yan HX, Liu SQ, Chen L, Wu MC, Wang HY. Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas. World J Gastroenterol 2008; 14(37): 5665-5673 [PMID: 18837082 DOI: 10.3748/wjg.14.5665]
Corresponding Author of This Article
Hong-Yang Wang, International Cooperation Laboratory on Signal Transduction, Eastern Hepatobilliary Surgery Institute, Second Military Medical University, Shanghai 200438, China. hywangk@online.sh.cn
Article-Type of This Article
Liver Cancer
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 7, 2008; 14(37): 5665-5673 Published online Oct 7, 2008. doi: 10.3748/wjg.14.5665
Table 1 Expression of five cell adhesion molecules in HCCs n (%)
E-cadherin
α-catenin
β-catenin
γ-catenin
p120
Normal
40 (41.2)
32 (35.0)
42 (35.0)
37 (37.5)
35 (42.5)
Reduced
41 (42.3)
46 (65.0)
42 (65.0)
50 (62.5)
47 (57.5)
Absent
16 (16.5)
19
13
10
15
Table 2 Distribution of complex expression in HCCs
Membrane
Cytoplasm
Nucleus
E-cadherin
97
0
0
α-catenin
70
27
0
β-catenin
55
36
6
γ-catenin
63
34
0
p120
65
32
0
Table 3 Relationship between expression of E-cadherin/catenin complex and histological features and clinical parameters in HCCs
E-cadherin
α-catenin
β-catenin
γ-catenin
p120ctn
n
+/-
+/-
+/-
+/-
+/-
Histological grade
I-II
23
20/3
19/4
22/1
20/3
19/4
III
58
17/41
11/47
20/38
11/47
15/43
IV
16
3/13
2/14
2/14
3/13
1/15
P
0.000
0.000
0.000
0.000
0.000
Histological stage
I-II
47
24/23
22/25
27/20
25/22
27/20
III
37
12/25
5/32
10/27
10/27
6/31
IV
14
4/10
3/11
5/9
2/12
2/12
P
0.136
0.003
0.017
0.007
0.000
Tumor size
< 3 cm
29
15/14
17/12
18/11
17/12
19/10
3-10 cm
50
18/32
10/40
16/34
13/37
12/38
> 10 cm
18
7/11
5/13
8/10
7/11
4/14
P
0.382
0.002
0.034
0.016
0.000
Capsular invasion
Present
9
7/2
6/3
6/3
5/4
5/4
Absent
88
33/55
26/62
36/52
32/56
30/58
P
0.003
0.055
0.169
0.295
0.277
Satellite nodules
Present
24
10/14
8/16
12/12
7/17
8/16
Absent
73
30/43
24/40
30/43
30/43
27/46
P
1.000
1.000
0.483
0.341
0.811
Vascular invasion
Present
26
8/18
8/18
12/14
10/16
7/19
Absent
71
32/39
24/47
30/41
27/44
28/43
P
0.249
1.000
0.818
1.000
0.341
Lymph node permission
Present
17
4/13
3/14
8/9
6/11
5/12
Absent
80
36/44
29/51
34/46
31/49
30/50
P
0.114
0.116
0.791
1.000
0.59
Intrahepatic metastasis
Present
32
7/25
5/27
9/23
7/25
6/26
Absent
65
33/32
27/38
33/32
30/35
29/36
P
0.008
0.012
0.049
0.026
0.014
AFP-value
< 20 ng/dL
28
6/12
13/15
16/12
14/14
15/13
> 20 ng/dL
69
24/45
19/50
26/43
23/46
20/49
P
0.068
0.096
0.113
0.167
0.035
Table 4 Relationship between E-cadherin and catenin expressions in HCCs
α-catenin
β-catenin
γ-catenin
p120
+
-
+
-
+
-
+
-
E-catenin
+
28
12
33
7
29
11
31
9
-
4
53
9
48
8
49
4
53
P
0.000
0.000
0.000
0.000
Citation: Zhai B, Yan HX, Liu SQ, Chen L, Wu MC, Wang HY. Reduced expression of E-cadherin/catenin complex in hepatocellular carcinomas. World J Gastroenterol 2008; 14(37): 5665-5673